Work

A phase I study of the CDK4/6 inhibitor, palbociclib plus 5-fluorouracil (5FU) in patients with advanced solid tumor malignancies (NCT01522989).

Year: 2016

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2016.34.15_suppl.2589

Authors: Michael J. Pishvaian, Hongkun Wang, Brandon George Smaglo, Jennifer Gao, Laura Macke, Erica Redmond, Eva Camilla Andersson Permaul, Supti Sen, Damian L. McCarthy, Bhaskar Kallakury, Stephen V. Liu, Aiwu Ruth He, Jimmy J. Hwang, Sandra M. Swain, John Marshall, Paula Raffin Pohlmann

Institutions: Georgetown University, Georgetown Lombardi Comprehensive Cancer Center, National Institutes of Health, National Cancer Institute, Carolinas Medical Center, Levine Cancer Institute, MedStar Washington Hospital Center, NRG Oncology

Language: English

Topic: Advanced Breast Cancer Therapies

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2503569005

Cites:

Cited by: 3

Related to: 10